We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Symbicort SMART Satisfaction From Patient Perspective 2009

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00946452
First Posted: July 27, 2009
Last Update Posted: March 18, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
To characterize the level of asthma control and patient satisfaction amongst diagnosed asthma sufferers who are currently receiving Symbicort Maintenance and Reliever Therapy (SMART) in Malaysia.

Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Symbicort SMART Satisfaction From Patient Perspective 2009

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Score level of Satisfaction in Asthma Treatment Questionnaire (SATQ) [ Time Frame: After 3 months on SMART - once ]
  • Score level of Asthma Control Test (ACT) [ Time Frame: After 3 months on SMART - once ]

Enrollment: 205
Study Start Date: August 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic
Criteria

Inclusion Criteria:

  • Have been prescribed Symbicort SMART (1 or 2 inhalation twice daily) by their Dr's for the past 3 months
  • Informed consent

Exclusion Criteria:

  • Symbicort SMART treatment < 3 months
  • Patients requiring short courses of oral steroids more than twice in a month
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00946452


Locations
Malaysia
Research Site
Petaling Jaya, Selangor, Malaysia
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Liam Chong Kin, Professor UMMC
  More Information

Responsible Party: MC MD, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00946452     History of Changes
Other Study ID Numbers: NIS-RMY-SYM-2009/1
First Submitted: July 24, 2009
First Posted: July 27, 2009
Last Update Posted: March 18, 2010
Last Verified: March 2010

Keywords provided by AstraZeneca:
Control
Satisfaction

Additional relevant MeSH terms:
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents